These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17192841)

  • 1. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents.
    Koro C; Barrett S; Qizilbash N
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):485-92. PubMed ID: 17192841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis.
    Koro CE; Sowell MO; Stender M; Qizilbash N
    Clin Ther; 2008 Mar; 30(3):535-42. PubMed ID: 18405791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
    Stockl KM; Le L; Zhang S; Harada AS
    Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
    Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.
    Govindarajan R; Ratnasinghe L; Simmons DL; Siegel ER; Midathada MV; Kim L; Kim PJ; Owens RJ; Lang NP
    J Clin Oncol; 2007 Apr; 25(12):1476-81. PubMed ID: 17442990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study.
    Hippisley-Cox J; Vinogradova Y; Coupland C; Parker C
    Arch Gen Psychiatry; 2007 Dec; 64(12):1368-76. PubMed ID: 18056544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
    Hartung DM; Touchette DR; Bultemeier NC; Haxby DG
    Pharmacotherapy; 2005 Oct; 25(10):1329-36. PubMed ID: 16185176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study.
    Brauchli YB; Jick SS; Curtin F; Meier CR
    J Am Acad Dermatol; 2008 Mar; 58(3):421-9. PubMed ID: 18194825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.
    Lin HC; Hsu YT; Kachingwe BH; Hsu CY; Uang YS; Wang LH
    J Clin Pharm Ther; 2014 Aug; 39(4):354-60. PubMed ID: 24661226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and demographic characteristics of patients receiving different oral hypoglycemic agents.
    Gomes T; Juurlink DN; Lipscombe LL; Mamdani MM
    Pharmacoepidemiol Drug Saf; 2009 Aug; 18(8):756-60. PubMed ID: 19399918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refill compliance in type 2 diabetes mellitus: a predictor of switching to insulin therapy?
    Spoelstra JA; Stolk RP; Heerdink ER; Klungel OH; Erkens JA; Leufkens HG; Grobbee DE
    Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):121-7. PubMed ID: 12642975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
    Aquilante CL; Zhang W; McCollum M
    Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of thiazolidinediones and fracture risk.
    Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR
    Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications.
    Velicer CM; Dublin S; White E
    Prostate Cancer Prostatic Dis; 2007; 10(1):46-51. PubMed ID: 17033617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-diabetic drug use and the risk of motor vehicle crash in the elderly.
    Hemmelgarn B; Lévesque LE; Suissa S
    Can J Clin Pharmacol; 2006; 13(1):e112-20. PubMed ID: 16585812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
    Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
    Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.
    Idris I; Warren G; Donnelly R
    Arch Intern Med; 2012 Jul; 172(13):1005-11. PubMed ID: 22688528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database.
    Simeone JC; Quilliam BJ
    Ann Pharmacother; 2012 Feb; 46(2):157-68. PubMed ID: 22234990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.